No price history available.

Based on consensus from external analysts. Not Kvantra's opinion.

Knight Therapeutics Inc., a specialty pharmaceutical enterprise established in Montreal, Canada in 2013, operates globally, with a strong presence across Canada and Latin America. The company's core business revolves around the development, acquisition, in-licensing, out-licensing, promotion, and distribution of a diverse portfolio encompassing pharmaceutical products, consumer health goods, and medical devices. Its extensive product catalog features treatments such as Nerlynx, prescribed for extended adjuvant and metastatic breast cancer; Tafasitamab, used for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib, targeting metastatic cholangiocarcinoma; Trelstar, addressing advanced prostate cancer and pain associated with endometriosis; Vidaza, indicated for myelodysplastic syndrome; Abraxane, for metastatic pancreatic adenocarcinoma; Halaven, for metastatic breast cancer and soft tissue sarcoma; and Lenvima, useful in differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. The company's offerings further include Ladevina, for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix, for metastatic prostate cancer; Karfib, for relapsed or refractory multiple myeloma; Leprid, for advanced prostate cancer; and Rembre, for chronic myeloid leukemia. For infectious diseases, it provides Ambisome and Cresemba for fungal infections, along with Impavido for leishmaniasis. Other notable products include Exelon, managing mild to moderately severe dementia; Ibsrela, for irritable bowel syndrome with constipation; Salofalk, for ulcerative colitis; Ursofalk, to treat biliary cirrhosis; Imvexxy, for moderate to severe dyspareunia; Bijuva, for moderate to severe vasomotor symptoms linked to menopause in women with intact uteri; Fibridoner, for idiopathic pulmonary fibrosis; Toliscrin DPI, addressing pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2, for severe acute or resistant chronic infections; and Tobradosa Haler, for chronic lung infections. Beyond its product-focused endeavors, Knight Therapeutics Inc. also provides financing to other life science companies and makes strategic investments in life sciences venture capital funds.

• PT Tempo Scan Pacific Tbk
• Ironwood Pharmaceuticals, Inc.
• Mochida Pharmaceutical Co., Ltd.
• Beijing Science Sun Pharmaceutical Co., Ltd.
• Shanghai Kaibao Pharmaceutical CO.,Ltd
• Jianmin Pharmaceutical Group Co.,Ltd.
• FDC Limited
• Jiangsu Lianhuan Pharmaceutical Co., Ltd.